Filtered By:
Education: Learning
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 40 results found since Jan 2013.
Opportunities to accelerate immunization progress in middle-income countries
Vaccine. 2023 Jul 15:S0264-410X(23)00782-X. doi: 10.1016/j.vaccine.2023.06.079. Online ahead of print.ABSTRACTThere has been increasing recognition of vaccine access challenges in middle-income countries and the need for increased action, particularly in countries that are not eligible for or have transitioned out of Gavi, the Vaccine Alliance support. These countries' immunization systems are more vulnerable than ever as the COVID-19 pandemic exacerbates existing programme challenges, increasing the risk of delayed vaccine introductions, backsliding immunization coverage rates, and increased coverage inequity. The potenti...
Source: Vaccine - July 17, 2023 Category: Allergy & Immunology Authors: Jason Zhu Clarke B Cole Johanna Fihman Alex Adjagba Mira Dasic Tania Cernuschi Source Type: research
Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
CONCLUSIONS: Overall, PCV13 demonstrated better protection than PPV23 against pneumococcal disease and all-cause respiratory outcomes in the included studies. Where evaluated, sequential PCV13/PPV23 vaccination showed little benefit over PCV13 alone. Results support the use of PCVs to protect against pneumococcal disease and respiratory infections in adults.PMID:36681604 | DOI:10.1016/j.arbres.2022.12.015
Source: Archivos de Bronconeumologia - January 21, 2023 Category: Respiratory Medicine Authors: Eileen M Dunne Catia Cilloniz Claire von Mollendorf Joseph Lewnard Lindsay R Grant Mary P E Slack Luis Jodar Christian Theilacker Bradford D Gessner Source Type: research
Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research
Engineering a novel immunogenic chimera protein utilizing bacterial infections associated with atherosclerosis to induce a deviation in adaptive immune responses via Immunoinformatics approaches
This study may pave the path for combat against atherosclerosis.PMID:35568333 | DOI:10.1016/j.meegid.2022.105290
Source: Infection, Genetics and Evolution - May 14, 2022 Category: Genetics & Stem Cells Authors: Kiarash Saleki Parsa Alijanizade Saead Moradi Abolfazl Rahmani Mohammad Banazadeh Mohamad Hosein Mohamadi Farzad Shahabi Hamid Reza Nouri Source Type: research
